Clinical Trial Update: Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant study of Vebreltinib for MET-altered, potentially resectable non-small cell lung cancer (stage IIIA-IIIB, N2); the trial is not yet recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Vebreltinib (vebreltinib)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Potentially Resectable MET-altered Non-Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING